CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$1.99 USD
-0.08 (-3.86%)
Updated Nov 14, 2024 03:59 PM ET
After-Market: $1.99 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.99 USD
-0.08 (-3.86%)
Updated Nov 14, 2024 03:59 PM ET
After-Market: $1.99 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Zacks News
KemPharm (KMPH) Soars on FDA Nod for ADHD Treatment, Azstarys
by Zacks Equity Research
The FDA approves KemPharm's (KMPH) NDA for Azstarys for the treatment of attention deficit hyperactivity disorder in patients aged six years and older. Shares rise.
Aerie (AERI) Rises Despite Q4 Earnings Miss, Revenues Top Mark
by Zacks Equity Research
Aerie (AERI) up more than 16% despite reporting a wider-than-expected loss in the fourth quarter of 2020. Revenues beat estimates.
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
Pacira's (PCRX) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Exparel sales rise year over year.
Esperion (ESPR) Q4 Earnings Miss, Coronavirus Woes Continue
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.
Tilray (KL) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Tilray (KL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for April 28th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 28th
Top Ranked Momentum Stocks to Buy for April 27th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 27th
Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment
by Zacks Equity Research
Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.
Company News For Jan 6, 2020
by Zacks Equity Research
Companies In The News Are: CANF, LW, INCY, NOVN
Company News For Dec 27, 2019
by Zacks Equity Research
Companies In The News Are: QGEN, IMMU, CANF, SBPH
All You Need to Know About Can-Fite (CANF) Rating Upgrade to Strong Buy
by Zacks Equity Research
Can-Fite (CANF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.